Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie (ABBV) is conducting a Phase 1/2 clinical study titled ‘A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma.’ The study aims to assess the safety and efficacy of ABBV-453, a BCL-2 inhibitor, in treating relapsed/refractory multiple myeloma (R/R MM). This research is significant as it explores new treatment avenues for a challenging plasma cell disease.
The study tests the investigational drug ABBV-453, administered orally, alone or in combination with other antimyeloma agents like daratumumab, dexamethasone, and pomalidomide. These treatments aim to reduce disease activity and manage adverse events in patients with R/R MM.
The study employs a randomized, open-label, sequential intervention model with no masking. Its primary purpose is treatment-focused, aiming to identify the optimal dosing strategy for ABBV-453 in combination therapies.
Key dates for the study include its start on April 17, 2025, with the latest update submitted on August 27, 2025. The study is expected to run for approximately 4.5 years, highlighting its long-term commitment to understanding ABBV-453’s therapeutic potential.
This clinical update could influence AbbVie’s stock performance positively, given the potential breakthrough in treating multiple myeloma. Investors may view this as a strategic move to strengthen AbbVie’s oncology portfolio, especially in a competitive landscape where advancements in cancer treatment are highly valued.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.